Tenaya Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	33.16	31.08	18.41	7.81	4.56
Research & Development	98.04	94.54	54.39	31.1	23.15
Operating Expenses	131.19	125.62	72.81	38.91	27.71
Operating Income	-131.19	-125.62	-72.81	-38.91	-27.71
Other Expense / Income	-7.11	-1.96	-0.09	-0.52	-1.48
Pretax Income	-124.08	-123.67	-72.72	-38.4	-26.23
Net Income	-124.08	-123.67	-72.72	-38.4	-26.23
Shares Outstanding (Basic)	74	45	18	1	5
Shares Outstanding (Diluted)	74	45	18	1	5
Shares Change	64.61%	152.75%	1724.33%	-78.56%	-
EPS (Basic)	-1.68	-2.76	-4.10	-39.50	-5.78
EPS (Diluted)	-1.68	-2.76	-4.10	-39.50	-5.78
Free Cash Flow	-103.31	-125.05	-85.93	-45.21	-27.02
Free Cash Flow Per Share	-1.40	-2.79	-4.85	-46.51	-5.96
EBITDA	-112.27	-114.95	-68.7	-35.91	-24.24
Depreciation & Amortization	11.82	8.71	4.03	2.48	1.99
EBIT	-124.08	-123.67	-72.72	-38.4	-26.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).